MétaCan
Menu
Back to cohort
Record W4386968516 · doi:10.1016/j.jval.2023.08.008

Real-World Cost-Effectiveness of Pulmonary Vein Isolation for Atrial Fibrillation: A Target Trial Approach

2023· article· en· W4386968516 on OpenAlexaff
Miquel Serra‐Burriel, Helena Aebersold, Fabienne Foster‐Witassek, Michael Coslovsky, Nicolas Rodondi, Manuel R. Blum, Christian Sticherling, Giorgio Moschovitis, Jürg H. Beer, Tobias Reichlin, Philipp Krisai, Stefanie Aeschbacher, Rebecca E. Paladini, Michael Kühne, Stefan Osswald, David Conen, Stefan Felder, Matthias Schwenkglenks

Bibliographic record

VenueValue in Health · 2023
Typearticle
Languageen
FieldMedicine
TopicAtrial Fibrillation Management and Outcomes
Canadian institutionsMcMaster UniversityPopulation Health Research Institute
FundersServierSchweizerische HerzstiftungUniversität BaselBiosense WebsterSchweizerischer Nationalfonds zur Förderung der Wissenschaftlichen ForschungFoundation for Cardiovascular ResearchDaiichi Sankyo EuropeEuropean CommissionSanofiAstraZenecaAmgenPfizerBoston Scientific CorporationNational Science Foundation
KeywordsMedicineContext (archaeology)Cost effectivenessAtrial fibrillationRandomized controlled trialHazard ratioQuality-adjusted life yearObservational studyCohortIncremental cost-effectiveness ratioInternal medicineEmergency medicineConfidence intervalIntensive care medicine

Abstract

fetched live from OpenAlex

OBJECTIVES: Randomized controlled trials of pulmonary vein isolation (PVI) for treating atrial fibrillation (AF) have proven the procedure's efficacy. Studies assessing its empirical cost-effectiveness outside randomized trial settings are lacking. We aimed to evaluate the effectiveness and cost-effectiveness of PVI versus medical therapy for AF. METHODS: We followed a target trial approach using the Swiss-AF cohort, a prospective observational cohort study that enrolled patients with AF between 2014 and 2017. Resource utilization and cost information were collected through claims data. Quality of life was measured with EQ-5D-3L utilities. We estimated incremental cost-effectiveness ratios (ICERs) from the perspective of the Swiss statutory health insurance system. RESULTS: Patients undergoing PVI compared with medical therapy had a 5-year overall survival advantage with a hazard ratio of 0.75 (95% CI 0.46-1.21; P = .69) and a 19.8% SD improvement in quality of life (95% CI 15.5-22.9; P < .001), at an incremental cost of 29 604 Swiss francs (CHF) (95% CI 16 354-42 855; P < .001). The estimated ICER was CHF 158 612 per quality-adjusted life-year (QALY) gained within a 5-year time horizon. Assuming similar health effects and costs over 5 additional years changed the ICER to CHF 82 195 per QALY gained. Results were robust to the sensitivity analyses performed. CONCLUSIONS: Our results show that PVI might be a cost-effective intervention within the Swiss healthcare context in a 10-year time horizon, but unlikely to be so at 5 years, if a willingness-to-pay threshold of CHF 100 000 per QALY gained is assumed. Given data availability, we find target trial designs are a valuable tool for assessing the cost-effectiveness of healthcare interventions outside of randomized controlled trial settings.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.034
metaresearch head score (Gemma)0.055
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.034
Threshold uncertainty score0.181

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0340.055
Meta-epidemiology (narrow)0.0030.001
Meta-epidemiology (broad)0.0070.011
Bibliometrics0.0010.001
Science and technology studies0.0010.002
Scholarly communication0.0040.004
Open science0.0020.003
Research integrity0.0030.006
Insufficient payload (model declined to judge)0.0090.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.172
GPT teacher head0.409
Teacher spread0.236 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2023
Admission routes1
Has abstractno

Explore more

Same venueValue in HealthSame topicAtrial Fibrillation Management and OutcomesFrench-language works237,207